|
(Health-NewsWire.Net, December 12, 2015 )
Discovery Stage Partnering Terms and Agreements 2010-2015 Size and Share Published in 2015-12-01 Available for US$ 3495 at Researchmoz.us
Description
The Discovery Stage Partnering Terms and Agreements 2010-2015 report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare companies.
The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
Download Sample of this Report at: http://www.researchmoz.us/enquiry.php?type=S&repid=487834
This report contains over 3,000 links to online copies of actual discovery stage deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of discovery stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner discovery stage compounds/products.
Chapter 3 provides an overview of discovery stage deals strategy and deal structure including numerous case studies, whilst Chapter 4 gives an overview of the various payment strategies used in discovery stage deals.
Chapter 5 provides a review of discovery stage deal making since 2010. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 6 provides a detailed analysis of discovery stage payment terms including average headline, upfront, milestone and royalty rates for discovery deals.
Chapter 7 presents a review of the leading discovery stage deal by headline value.
Chapter 8 provides a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of discovery stage deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 9 provides a comprehensive and detailed review of discovery stage partnering deals signed and announced since 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
A comprehensive directory of discovery stage partnering deals since 2010 forms Chapter 10.
The report also includes numerous tables and figures that illustrate the trends and activities in discovery stage partnering and deal making since 2010.
In addition, a comprehensive appendix is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery stage products and compounds.
Discovery Stage Partnering Terms and Agreements 2010-2015 provides the reader with the following key benefits:
In-depth understanding of discovery stage deal trends since 2010
Access to headline, upfront, milestone and royalty data
Comprehensive access to over 3,000 discovery stage deals together with contract documents if available
Detailed access to actual discovery stage deals entered into by the leading fifty big pharma and big biotech companies along with other biopharma companies
Analysis of the structure of discovery stage agreements with numerous real life case studies
Identify leading discovery stage deals by value since 2010
Identify the most active discovery stage dealmakers since 2010
Full listing of discovery stage deals by company A-Z, phase of development, deal type, therapy and technology focus
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Make an Enquiry: http://www.researchmoz.us/enquiry.php?type=E&repid=487834
Table of Content
Chapter 1 – Introduction
Chapter 2 – Why do companies partner at discovery stage?
2.1. Introduction
2.2. The role of discovery stage partnering
2.2.1. In-licensing at discovery stage
2.2.2. Out-licensing at discovery stage
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into discovery stage partnering deals
2.4.1. Licensors reasons for entering discovery stage deals
2.4.2. Licensees reasons for entering discovery stage deals
2.5. The future of discovery stage partnering deals
Chapter 3 – Discovery stage deal strategies and structure
3.1. Introduction
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical/biotech
3.2.1.1. Discovery and preclinical stage partnering case studies
3.2.1.1.a. Case study: LEO Pharma - 4SC
3.2.1.1.b. Case study: Heptares Therapeutics - Cubist
3.2.1.1.c. Case study: Incyte – Agenus Bio
3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec
3.2.2. Partnering later in pharmaceutical/biotech
3.2.2.1. Clinical stage partnering case studies
3.2.2.1.a. Case study: Servier – GeNeuro
3.2.2.1.b. Case study: Teva – Xenon Pharmaceuticals
3.2.2.1.c. Case study: AstraZeneca - Ardelyx
3.2.2.1.d. Case study: Baxter – Onconova Therapeutics
3.3. Early and later stage partnering – a risk/cost comparison
3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure licensing agreements
3.6.1.a. Case study : Pfizer – Spark Therapeutics
3.6.1.b. Case study : Contrafect – Trellis Bioscience
3.7. Multicomponent discovery stage partnering agreements
3.7.1.a. Example multicomponent early stage clauses
3.7.1.a. Case study: Tracon –Boehringer Ingelheim – Macrogenics
3.7.1.b. Case study: Fibrocell Science – Intrexon
Browse All Pharmaceuticals and Healthcare Market Research Reports at http://www.researchmoz.us/pharmaceutical-and-healthcare-market-reports-1.html
About ResearchMoz
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives.
Contact Us:
ResearchMoz
Mr. Nachiket Ghumare, +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
sales@researchmoz.us <||>rnhttp://www.researchmoz.us/
For More Report Click Here @ http://www.prweb.com/search.aspx?search-releases=researchmoz&hitsPerPage=20
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
|
